

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

C07C 229/42, A61K 31/215

A1

(11) International Publication Number:

WO 96/00716

(43) International Publication Date:

11 January 1996 (11.01.96)

(21) International Application Number:

PCT/IB95/00524

(22) International Filing Date:

28 June 1995 (28.06.95)

(30) Priority Data:

94810382.5

29 June 1994 (29.06.94)

EP

(34) Countries for which the regional or international application was filed:

AT et al.

(71) Applicant (for all designated States except US): CIBA-GEIGY AG [CH/CH]; Klybeckstrasse 141, CH-4002 Basle (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): SALLMANN, Alfred [CH/CH]; Joachimsackerstrasse 12, CH-4103 Bottmingen (CH).



(74) Common Representative: CIBA-GEIGY AG; Patentabteilung, Klybeckstrasse 141, CH-4002 Basle (CH).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: NEW SALTS OF 2-[(2,6-DICHLOROPHENYL)AMINE]PHENYLACETOXYACETIC ACID WITH ORGANIC BASIC CATIONS



(57) Abstract

A salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with an organic basic cation of formula (I); Wherein R_1 and R_2 independently are lower alkyl, or if R_1 is hydrogen $H-N(R_1)(R_2)$ has the meaning of arginine or lysine or if R_1 is methyl $H-N(R_1)(R_2)$ has the meaning of N-methylglucamine. This compound possesses analgesic activity as well as antiinflammatory activity, suitable in the treatment of conditions such as rheumatoid arthritis, ankylosing spondylitis, lumbar pains, luxations and ocular inflammation. The compound further has an improved stability in aqueous solutions in comparison to the alkali metal salts, e.g. sodium and potassium.


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

New salts of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with organic basic cations

The present invention relates to new salts of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with organic basic cations of formula I



wherein R_1 and R_2 independently are lower alkyl, or if R_1 is hydrogen $\text{H}-\text{N}(\text{R}_1)(\text{R}_2)$ has the meaning of arginine or lysine or if R_1 is methyl $\text{H}-\text{N}(\text{R}_1)(\text{R}_2)$ has the meaning of N-methylglucamine, to processes for the preparation of the said compounds, to pharmaceutical compositions comprising them and to their use as active ingredients in medicaments.

Hereinbefore and hereinafter, "lower" radicals and compounds are to be understood as being, for example, those having up to and including 7, preferably up to and including 4 carbon atoms (cations).

Lower alkyl is, for example, C_1 - C_4 -alkyl, such as methyl, ethyl, propyl or butyl.

EP-0119932 discloses 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid and its monobasic salts with pharmaceutically acceptable organic or inorganic cations. These compounds are of therapeutical use with anti-inflammatory and analgesic pharmacological properties, suitable for the treatment of numerous clinic conditions, such as rheumatoid arthritis, ankylosing spondylitis, lumbar pains, traumatism, luxations, etc. The

- 2 -

compounds possess also analgetic activity.

However, none of the claimed salts in EP-0119932 have been described or exemplified.

It has now been found, surprisingly, that salts of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with organic bases, such as arginine, lysine, diethylamine and N-methylglucamine are unexpectedly stable for at least 25 hours in aqueous solutions and that potassium- and sodium salts of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid are time-dependently instable in aqueous solutions.

The salts of the present invention can be prepared in a manner known per se by reacting 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic with a substantially equimolar amount of a compound of formula Ia



wherein R_1 and R_2 independently are lower alkyl, or if R_1 is hydrogen $H-N(R_1)(R_2)$ has the meaning of arginine or lysine or if R_1 is methyl $H-N(R_1)(R_2)$ has the meaning of N-methylglucamine, in an aqueous solution or in a suitable protic or aprotic organic solvent such as an aliphatic or cycloaliphatic ether, for example diethylether, tetrahydrofuran or dioxane or a lower alcohol, such as methanol or ethanol at a temperature of from 0°C to the boiling temperature of the solvent, preferably at a temperature from 10°C to 30°C. The salts are recovered by standard methods such as filtration if they are insoluble in the original medium or, if they are soluble in that medium, the salt is precipitated by evaporation of the solvent or by addition of a non-solvent for the salt.

The compounds of the present invention may be administered as an aqueous solution for parenteral or intravenous injection or an oily suspension for intramuscular injection.

The compounds of the present invention possess surprisingly an improved stability in aqueous solution in comparison to the the alkali metal salts, e.g. sodium and potassium as

- 3 -

demonstrated herein thereafter. The compounds of the present invention possess antiinflammatory activity, suitable in the treatment of conditions such as rheumatoid arthritis, ankylosing spondylitis, lumbar pains, luxations and also ocular inflammation. The compounds possess also analgesic activity.

The invention relates especially to salts of formula I wherein R_1 and R_2 independently are ethyl, or if R_1 is hydrogen $H-N(R_1)(R_2)$ has the meaning of L-arginine or L-lysine or if R_1 is methyl $H-N(R_1)(R_2)$ has the meaning of N-methylglucamine.

The invention relates specifically to the compound of formula I mentioned in the Examples thereafter.

The pharmaceutical compositions according to the invention, which comprise the compound according to the invention, are for enteral, such as oral, and also rectal, and parenteral administration to (a) warm-blooded animal(s), and comprise the pharmacological active ingredient on its own or together with a pharmaceutically acceptable carrier. The daily dose of active ingredients is dependent on the age and individual condition as well as on the mode of administration.

The novel pharmaceutical compositions comprise, for example, from about 10 % to about 80 %, preferably from about 20 % to about 60 %, active ingredient. Pharmaceutical compositions according to the invention for enteral and/or parenteral administration are, for example, those in unit dose form, such as dragées, tablets, capsules or suppositories, as well as ampoules. They can be prepared in a manner known *per se*, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising process. For example, pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, optionally granulating a resulting mixture, and, if desired, processing the mixture or granules, if necessary with the addition of suitable excipients, to form tablets or dragée cores.

Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using, for example, corn, wheat, rice or potato starch, gelatin, tragaanth, methylcellulose and/or polyvinylpyrrolidone, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar, alginic acid

- 4 -

or a salt thereof, such as sodium alginate. Excipients are especially flow agents, flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragée cores are provided with suitable, optionally enteric coatings, there being used *inter alia* concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Colourings or pigments may be added to the tablets or dragée coatings, for example for identification purposes or to indicate different doses of active ingredient.

Other orally administrable pharmaceutical compositions are dry-filled capsules comprising gelatin, and also soft sealed capsules comprising gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example in admixture with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and, if desired, stabilisers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffine oil or liquid polyethylene glycol, to which stabilisers may also have been added.

Suitable rectally administrable pharmaceutical compositions are, for example, suppositories that comprise a combination of the active ingredient with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycol or higher alkanols. There may also be used gelatin rectal capsule, which comprise a composition of the active ingredient with a base material. Suitable base materials are, for example, liquid triglycerides, polyethylene glycol or paraffin hydrocarbons.

Suitable for parenteral administration are especially aqueous solutions of an active ingredient in water-soluble form, for example in the form of a water-soluble salt, and also suspensions of the active ingredient, such as corresponding oily injection suspensions, there being used suitable lipophilic solvents or vehicles, such as fatty oils, for example sesame oils, or synthetic fatty acid esters, for example ethyl oleate or triglycerides, or aqueous injection suspensions that comprise viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, optionally, stabilisers.

- 5 -

The invention relates also to the use of the compound of formula I, preferably in the form of pharmaceutical compositions. The dose of active ingredient is dependent on the species of warm-blooded animal, the age and the individual condition, as well as on the mode of administration. In normal cases, the approximate daily dose in the case of administration to a patient weighing about 75 kg is estimated to be from about 5 mg to about 1000 mg, especially from about 10 mg to about 200 mg. The dose can be administered all at once or may be divided into several, for example from 2 to 4, individual doses. Pharmaceutical compositions in unit dose form thus comprise from about 5 mg to about 250 mg, especially from about 20 mg to about 100 mg, of active ingredient.

Examples

Example 1: To a solution of 2.46 g of L-arginine in 70.6 ml of water 5.0 g of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid are added with stirring. The solution is filtered through a glassfibre filter. The aqueous filtrate is lyophilized. 60 ml of ethanol and 0.5 ml of water are added to the white residue. The slurry is warmed to 50°C with stirring. The resulting solution is cooled to 5°C with stirring. The mixture is allowed to stand for 1 hour at 5°C before the precipitated crystals are filtered off and dried under 0.1 mbar at 40°C during 15 hours. The L-arginine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid melts at 120-125°C.

Example 2: To a solution of 0.29 g of L-lysine in 20 ml of water 0.70 g of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid are added with stirring. The filtrate (pH 6.0) is filtered through a glassfibre filter and lyophilized. The yellowish residue, the L-lysine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid is obtained as an amorphous powder.

Example 3: 1.42 g of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid are dissolved in 60 ml of ether. 1.0 ml of diethylamine is added, thereafter the solution is stirred at room temperature for 3 minutes and evaporated under 20 mbar at 30°C. The white residue is stirred with 10 ml of ether at 5°C. The precipitated crystals are filtered off and recrystallized from ethyl acetate to give the diethylamine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid melting at 115-128°C with decomposition.

Example 4: To a solution of 1.77 g of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic


- 6 -

acid in 50 ml of water 0.98 g of N-methyl-D-glucamine are added. The solution is lyophilized. The residue is crystallized from ethanol yielding the N-methyl-D-glucamine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid, melting at 140-142°C.

Example 5: To a suspension of 6.0 g of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid in 135 ml of water a solution of 1.76 g of potassium bicarbonate in 33 ml of water are added with stirring. The suspension is stirred (at pH 7.3) for 5 hours. The opaque solution is filtered through a glassfibre filter. The filtrate is lyophilized. The residue is dissolved in 25 ml of ethyl acetate at 50°C. The resulting solution is cooled to 10°C and 100 ml of ether is added with stirring. The precipitated resin is isolated by decanting the solvent mixture. 20 mg of ethyl acetate are added to the resin and the mixture is stirred at 10°C for 4 hours. The resulting crystals are filtered off and dried at 0.1 mbar at room temperature. The potassium salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid melts at 122-130°C with decomposition.

Example 6: A solution of 0.1 g of the L-arginine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid in 3 ml of water is stored at room temperature for 25 hours. The solution is acidified with 1-N hydrochloric acid. The resulting suspension is extracted twice with ethyl acetate (2 x 20 ml). The combined organic extracts are dried over MgSO_4 and evaporated under 20 mbar at 30°C. The crystallized residue is dried under 0.1 mbar at room temperature during 15 hours. The proton NMR spectrum is determined on a Varian VXR 400 S spectrometer with Me_4Si as internal standard.

^1H NMR (C_6D_6): δ 3.66 (s, $\text{CH}_2\text{-a}$), 4.08 (s, $\text{CH}_2\text{-b}$)



The residue consists of pure 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid, which is confirmed by the NMR spectrum and also by thin layer chromatography (TLC).


- 7 -

Thin layer chromatography is performed with silica gel 60 F₂₅₄ plates (Merck). The system used for TLC is benzene-ethyl acetate-acetic acid 90: 5: 5 with spot location by spraying with a solution prepared by dissolving 0.5 g of K₂Cr₂O₇ in 80 ml of H₂O and adding 20 ml of concentrated H₂SO₄.

Example 7: A solution of 0.1 g of the potassium salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid in 3 ml of water is kept at room temperature for 25 hours. The solution is acidified with 1-N hydrochloric acid. The resulting suspension is extracted twice with ethyl acetate (2 x 20 ml). The combined organic extracts are dried over MgSO₄ and evaporated under 20 mbar at 30°C. The residue is dried under 0.1 mbar at room temperature during 15 hours. The proton NMR spectrum is determined in the same manner as in Example 6.

¹H NMR (C₆D₆): δ 3.66 (s, CH₂-a), 4.08 (s, CH₂-b), 3.488 (s, CH₂-c), 3.22 (s, CH₂-d).

The residue is a mixture of:



wherein

compound II is 2-[(2,6-dichlorophenyl)amine]acetic acid and compound III is 1-(2,6-dichlorophenyl)oxindole. According to the NMR data the mixture is composed of 95 % compound Ib, 3 % of compound II and 2 % of compound III. Compounds II and III can also be detected with TLC.

Example 8: Sample preparation and NMR analysis are accomplished in the same manner as in Example 6 replacing the L-arginine salt with the L-lysine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid. The NMR spectrum corresponds to 100 % compound Ib. The result is shown in Table 1.

Example 9: Sample preparation and NMR analysis are accomplished in the same manner as in Example 6 replacing the L-arginine salt with the diethylamine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid. The NMR spectrum corresponds to 100 % compound Ib. The result is shown in Table 1.

Example 10: Sample preparation and NMR analysis are accomplished in the same manner as in Example 6 replacing the L-arginine salt with the N-methyl-D-glucamine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid. The NMR spectrum corresponds to 100 % compound Ib. The result is shown in Table 1.

Example 11: Sample preparation and NMR analysis are accomplished in the same manner as in Example 7 replacing the potassium salt with sodium salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid. The NMR spectrum corresponds to a mixture composed of 95 % compound Ib, 3 % compound II and 2 % compound III. The result is shown in Table 1.

Table 1

salt	solubility in water	stability in water after 25 hours		
		acidification and extraction with ethyl acetate, yielding:		
		Ib	II	III
potassium	20 %	95 %	3 %	2 %
sodium	20 %	95 %	3 %	2 %
L-arginine	20 %	100 %	stable	
L-lysine	1 %	100 %		
diethylamine	20 %	100 %		
N-methyl-D-glucamine	20 %	100 %		

Example 12: Tablets, each comprising 10 mg of active ingredient, can be prepared as follows:

Composition (10 000 tablets)

active ingredient
lactose

100.0 g
450.0 g

- 9 -

potato starch	350.0 g
gelatin	10.0 g
talcum	60.0 g
magnesium stearate	10.0 g
silicon dioxide (highly dispersed)	20.0 g
ethanol q.s.	

The active ingredient is mixed with the lactose and 292 g of the potato starch, and the mixture is moistened with an ethanolic solution of the gelatin and granulated through a seive. After drying, the remainder of the potato starch, the magnesium stearate, the talcum and the silicon dioxide are mixed in and the mixture is compressed to form tablets, each weighing 100.0 mg and comprising 10.0 mg of active ingredient; if desired the tablets may be provided with dividing notches for finer adaptation of the dose.

Example 13: Hard gelatin capsules comprising 20 mg of active ingredient can be prepared, for example, as follows:

Composition (for 1000 capsules)

active ingredient	20.0 g
lactose	240.0 g
microcrystalline cellulose	30.0 g
sodium lauryl sulfate	2.0 g
magnesium stearate	8.0 g

The sodium lauryl sulfate is added to the lyophilised active ingredient through a sieve of 0.2 mm mesh size. The two components are intimately mixed. Then first the lactose is added through a sieve of 0.6 mm mesh size and then the microcrystalline cellulose is added through a sieve of 0.9 mm mesh size. The mixture is then intimately mixed again for 10 minutes. Finally the magnesium stearate is added through a sieve of 0.8 mm mesh size. After mixing for a further 3 minutes, size 0 hard gelatine capsules are each filled with 300 mg of the resulting formulations.

Example 14: Hard gelatin capsules comprising 100 mg of active ingredient can be prepared, for example, as follows:

- 10 -

Composition (for 1000 capsules)

active ingredient	100.0 g
lactose	250.0 g
microcrystalline cellulose	30.0 g
sodium lauryl sulfate	2.0 g
magnesium stearate	8.0 g

The sodium lauryl sulfate is added to the lyophilised active ingredient through a sieve of 0.2 mm mesh size. The two components are intimately mixed. Then first the lactose is added through a sieve of 0.6 mm mesh size and then the microcrystalline cellulose is added through a sieve of 0.9 mm mesh size. The mixture is then intimately mixed again for 10 minutes. Finally the magnesium stearate is added through a sieve of 0.8 mm mesh size. After mixing for a further 3 minutes, size 0 hard gelatin capsules are each filled with 390 mg of the resulting formulation.

Example 15: Film-coated tablets each comprising 50 mg of active ingredient can be prepared, for example, as follows:

Composition (for 1000 film-coated tablets)

active ingredient	50.0 g
lactose	100.0 g
corn starch	70.0 g
talcum	10.0 g
calcium stearate	2.0 g
hydroxypropylmethylcellulose	2.36 g
shellac	0.64 g
water	q.s.
methyl chloride	q.s.

The active ingredient, the lactose and 40 g of the corn starch are mixed and moistened with a paste prepared from 15 g of corn starch and water (with heating) and granulated. The granules are dried, the remainder of the corn starch, the talcum and the calcium stearate are added and mixed with the granules. The mixture is compressed to form tablets

- 11 -

(weight: 240 mg) which are then film-coated with a solution of the hydroxypropylmethylcellulose and the shellac in methylene chloride; final weight of the film-coated tablet: 283 mg.

Example 16: A 0.2 % injection or infusion solution of an active ingredient can be prepared, for example, as follows:

Composition (for 1000 ampoules)

active ingredient	5.0 g
sodium chloride	22.5 g
phosphate buffer pH = 7.4	300.0 g
demineralised water ad	2500.0 ml

The active ingredient and the sodium chloride are dissolved in 1000 ml of water and filtered through a microfilter. The buffer solution is added and the solution is made up to 2500 ml with water. For the preparation of unit dose forms, 1.0 ml or 2.5 ml portions are introduced into glass ampoules, which then each comprise 2.0 mg or 5.0 mg of active ingredient, respectively.

Example 17: A 1 % ointment (o/w emulsion), comprising an active ingredient, having the following composition:

active ingredient	1.0 g
catyl alcohol	3.0 g
glycerol	6.0 g
methylparaben	0.18 g
propylparaben	0.005 g
Arlacel 60	0.6 g
Tween 60	4.4 g
stearic acid	9.0 g
isopropyl palmitate	2.0 g
paraffin oil, viscous	10.0 g
demin. water, q.s. ad	100.0 g

Example 18: A 1 % gel, comprising an active ingredient, having the following


- 12 -

composition:

active ingredient	1.0 g
Carbopol 934 P	1.0 g
glycerol	3.0 g
isopropanol	25.0 g
Softigen® 767	0.2 g
demin. water, q.s. ad	100.0 g

What is claimed is:

1. A salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxycetic acid with an organic basic cation of formula I



- wherein R_1 and R_2 independently are lower alkyl, or if R_1 is hydrogen $H-N(R_1)(R_2)$ has the meaning of arginine or lysine or if R_1 is methyl $H-N(R_1)(R_2)$ has the meaning of N-methylglucamine.
2. A compound according to claim 1 of formula I, wherein R_1 and R_2 independently are ethyl, or if R_1 is hydrogen $H-N(R_1)(R_2)$ has the meaning of L-arginine or L-lysine or if R_1 is methyl $H-N(R_1)(R_2)$ has the meaning of N-methylglucamine.
3. A compound according to claim 1 of formula I in which the compound is the L-arginine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxycetic acid.
4. A compound according to claim 1 of formula I in which the compound is the L-lysine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxycetic acid.
5. A compound according to claim 1 of formula I in which the compound is the N-methyl-D-glucamine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxycetic acid.
6. A compound according to claim 1 of formula I in which the compound is the diethylamine salt of 2-[(2,6-dichlorophenyl)amine]phenylacetoxycetic acid.
7. A compound according to any one of claims 1 to 6 for use in a method for the therapeutic treatment of the human or animal body.


- 14 -

8. Pharmaceutical composition, characterized in that it comprises as an active ingredient an effective amount of a salt according to claim 1 and a pharmaceutically acceptable carrier or vehicle.

9. The use of a compound of formula I according to claim 1 and customary carriers for producing pharmaceutical preparations.

10. Use of a compound of formula I according to claim 1 for treating rheumatoid arthritis, ankylosing spondylitis, lumbar pains, luxations and ocular inflammation.

11. A process of preparing a salt according to claim 1, which consists in reacting 2-[(2,6-dichlorophenyl)amine]phenylacetoxyacetic acid with a substantially equimolar amount of a compound of formula Ia



(Ia),

wherein R_1 and R_2 independently are lower alkyl, or if R_1 is hydrogen $H-N(R_1)(R_2)$ has the meaning of arginine or lysine or if R_1 is methyl $H-N(R_1)(R_2)$ has the meaning of N-methylglucamine, in an aqueous solution or in a protic or aprotic organic solvent.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 95/00524

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C229/42 A61K31/215

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP-A-0 119 932 (PRODES S.A.) 26 September 1984 cited in the application see the whole document ---	1-10
Y	EP-A-0 521 393 (FARMAKA S.R.I.) 7 January 1993 see page 2, line 38 - line 44; claims 1-8 ---	1-10
Y	EP-A-0 271 709 (ALTERGON S.A.) 22 June 1988 see page 2 - page 3 ---	1-10
Y	AT-B-368 129 (GEROT PHARMAZEUTIKA G.M.B.H.) 15 January 1982 see the whole document ---	1-10
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 September 1995

Date of mailing of the international search report

0 2. 10. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 95/00524

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CH-A-651 821 (CIBA-GEIGY AG) 15 October 1985 see the whole document ---	1-10
Y	FR-A-2 500 751 (CIBA-GEIGY AG) 3 September 1982 see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 95/00524

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0119932	26-09-84	JP-C- 1598725	28-01-91
		JP-B- 2020627	10-05-90
		JP-A- 59205347	20-11-84
		US-A- 4548952	22-10-85
EP-A-0521393	07-01-93	IT-B- 1250636	21-04-95
EP-A-0271709	22-06-88	JP-C- 1680423	13-07-92
		JP-B- 3044062	04-07-91
		JP-A- 63152372	24-06-88
		US-A- 4948805	14-08-90
AT-B-368129	10-09-82	AT-A,B 368129	10-09-82
		JP-B- 1048258	18-10-89
		JP-C- 1565140	25-06-90
		JP-A- 57014566	25-01-82
CH-A-651821	15-10-85	NONE	
FR-A-2500751	03-09-82	GB-A- 2093693	08-09-82
		AT-A,B 370721	25-04-83
		AT-A- 380166	25-04-86
		CA-A- 1180008	25-12-84
		FR-A,B 2514348	15-04-83
		GB-A,B 2143528	13-02-85
		LU-A- 83945	13-12-82
		NL-A- 8100917	16-09-82
		SE-B- 448088	19-01-87
		SE-A- 8101064	18-08-82
		SE-A- 8203228	18-08-82
		US-A- 4784808	15-11-88
		US-A- 4407824	04-10-83
		US-A- 4551475	05-11-85
		US-A- 4619926	28-10-86